About Durata Therapeutics

Durata Therapeutics is a pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. Durata has completed two global Phase 3 clinical trials with its lead product candidate, dalbavancin, under investigation for the treatment of patients with acute bacterial skin and skin structure infections caused by susceptible gram-positive bacteria.
CONTACT: Allison Wey         Durata Therapeutics, Inc.         Vice President, Investor Relations and Public Affairs         (312) 219-7017         awey@duratatherapeutics.com

Durata Therapeutics, Inc. Logo

If you liked this article you might like

Why Durata Therapeutics (DRTX) Stock Hit a One-Year High Today

5 Stocks Moving on Unusual Volume

Emerging 'Superbugs' -- and Why Investors Should Care

2014 FDA Drug Approval Decision Calendar

Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan